Key result
Schizophrenia and mood disorders linked to ~3-fold higher Borna disease virus seroprevalence versus blood donors.
Why the study?
A reliable and specific method for detecting anti-Borna disease virus antibodies is needed to clarify the pathological significance of BDV infections in humans with psychiatric disorders.
Is Borna disease virus seropositivity associated with psychiatric disorders?
Cross-Sectional (n=4,393)
Is Borna disease virus seropositivity associated with psychiatric disorders?
Absolute Event Rate: 3.08% vs 1.09%
A novel ECLIA assay demonstrates a statistically significant association between Borna disease virus seropositivity and psychiatric disorders such as schizophrenia and mood disorders.
Observed association in Level 4 data is hypothesis-generating; leaves open a possible link but should not change psychiatric practice.
The prevalence of Borna disease virus (BDV)-specific antibodies among patients with psychiatric disorders and healthy individuals has varied in several reports using several different serological assay methods. A reliable and specific method for anti-BDV antibodies needs to be developed to clarify the pathological significance of BDV infections in humans. We developed a new electrochemiluminescence immunoassay (ECLIA) for the antibody to BDV that uses two recombinant proteins of BDV, p40 and p24 (full length). Using this ECLIA, we examined 3,476 serum samples from humans with various diseases and 917 sera from blood donors in Japan for the presence of anti-BDV antibodies. By ECLIA, 26 (3.08%) of 845 schizophrenia patients and 9 (3.59%) of 251 patients with mood disorders were seropositive for BDV. Among 323 patients with other psychiatric diseases, 114 with neurological diseases, 75 with chronic fatigue syndrome, 85 human immunodeficiency virus-infected patients, 50 with autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosis and 17 with leprosy, there was no positive case except one case each with alcohol addiction, AIDS, and dementia. Although 19 (1.36%) of 1,393 patients with various ocular diseases, 10 (1.09%) of 917 blood donors, and 3 (4.55%) of 66 multitransfused patients were seropositive for BDV-specific antigen, high levels of seroprevalence in schizophrenia patients and young patients (16 to 59 years old) with mood disorders were statistically significant. The immunoreactivity of seropositive sera could be verified for specificity by blocking with soluble p40 and/or p24 recombinant protein. Anti-p24 antibody was more frequent than p40 antibody in most cases, and in some psychotic patients antibody profiles showed only p40 antibody. Although serum positive for both p40 and p24 antibodies was not found in this study, the p40 ECLIA count in schizophrenia patients was higher than that of blood donors. Furthermore, we examined 90 sera from Japanese feral horses. Antibody profiles of control human samples are similar to that of naturally BDV-infected feral horses. We concluded that BDV infection was associated in some way with psychiatric disorders.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (1999) conducted a cross-sectional in Psychiatric disorders (n=4,393). Psychiatric disorders (schizophrenia and mood disorders) vs. Blood donors was evaluated on Seropositivity for Borna disease virus (BDV) antibodies. Seroprevalence of Borna disease virus antibodies was significantly higher in patients with schizophrenia (3.08%) and mood disorders (3.59%) compared to blood donors (1.09%).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: